Last reviewed 2026-06-10 · How we verify

Reducing the risk of fatal and nonfatal cardiovascular events — Treatment Landscape & Competitive Intelligence

Reducing the risk of fatal and nonfatal cardiovascular events (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Reducing the risk of fatal and nonfatal cardiovascular events, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Reducing the risk of fatal and nonfatal cardiovascular events

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Reducing the risk of fatal and nonfatal cardiovascular events:

• Reducing the risk of fatal and nonfatal cardiovascular events treatment updates — RSS
• Reducing the risk of fatal and nonfatal cardiovascular events treatment updates — Atom
• Reducing the risk of fatal and nonfatal cardiovascular events treatment updates — JSON

Cite this brief

Drug Landscape (2026). Reducing the risk of fatal and nonfatal cardiovascular events — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/reducing-the-risk-of-fatal-and-nonfatal-cardiovascular-events. Accessed 2026-06-10.

Related

• Reducing the risk of fatal and nonfatal cardiovascular events full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing